Business / Finance

RSS

Kinetic Concepts third quarter total revenue increases 5% to $531.4M

Kinetic Concepts, Inc. today reported third quarter 2011 total revenue of $531.4 million, an increase of 5% from the third quarter of 2010. Total revenue for the first nine months of 2011 was $1.55 billion, which represented a 4% increase from the prior-year period.

21 Oct 2011

Essilor revenue increases 9.7% for third quarter 2011

Essilor International, the world leader in ophthalmic optics, today announced its consolidated revenue for the nine months ended September 30, 2011.

21 Oct 2011

Tamandare Explorations is now Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system ("CNS"), including fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"), has announced the effectiveness of a company name change to Tonix Pharmaceuticals Holding Corp. and the commencement of trading under the stock symbol "TNXP".

20 Oct 2011

Alexion third quarter total revenues increase to $204.0 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and nine months ended September 30, 2011.

20 Oct 2011

Immdal sells its subsidiary Newport to Ewopharma

Immdal Limited ('Immdal'), a privately held Irish pharmaceutical healthcare group, today announced the sale of its subsidiary Newport Pharmaceuticals Limited ('Newport') to Swiss pharmaceutical company Ewopharma AG.

20 Oct 2011

GETINGE EPS increases 2.0% to SEK 5.92 for January - September 2011

GETINGE: Reporting period January - September. Orders received declined by 4.6% to SEK 15,579 M (16,331), and grew organically by 3.8%.

20 Oct 2011

St. Jude Medical third quarter net sales increase 12% to $1.383 billion

St. Jude Medical, Inc. today reported sales and net earnings for the third quarter ended October 1, 2011.

19 Oct 2011

NeoGenomics third quarter revenue increases 30% to $11.3 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the third quarter 2011.

19 Oct 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

Commercialization strategies for next-generation medicines

The Center for Biotechnology at Stony Brook University, in collaboration with Demy-Colton Life Science Advisors, and key opinion leaders from the biotech and biopharmaceutical industries, academia, medical research foundations, and investment community, has organized a two-day event to forge partnerships to accelerate the development of new treatments for some of the world's most devastating diseases affecting millions.

18 Oct 2011

NanoViricides President completes stock sales program

NanoViricides, Inc. announced that its President, Dr. Anil Diwan, has completed the programmed sale of the NanoViricides stock that he had obtained as a founder.

18 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

UnitedHealth Group's consolidated third quarter revenues increase 7% to $25.3B

UnitedHealth Group today reported third quarter results, highlighted by strong enrollment growth in each of UnitedHealthcare's benefits businesses and strong revenue growth at all Optum business units. Third quarter 2011 net earnings were $1.17 per share, with strong performance on all key financial and operational measures.

18 Oct 2011

Roche to acquire Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement to be acquired by Roche.

18 Oct 2011

Teva acquires Cephalon

Teva Pharmaceutical Industries Ltd. announced today that it has completed its acquisition of Cephalon, Inc. The combined company will have a significant presence in over 60 countries and generated approximately $20 billion in revenues on a pro-forma basis for the twelve months ended June 2011.

15 Oct 2011

WuXi PharmaTech announces acquisition of Abgent

WuXi PharmaTech Inc., a leading pharmaceutical, biotechnology and medical device research and development services company with operations in China and the United States, today announced the acquisition of Abgent, Inc., a provider of biological research reagent products and services based in Suzhou, China, and San Diego, California.

14 Oct 2011

Bruker acquires Center for Tribology

Bruker Corporation today announced the closing of its acquisition of Center for Tribology, Inc. (CETR) for $13 million in cash as an initial purchase price, with potential additional earn-out payments of up to $4 million in cash, depending on growth and profitability of the CETR-business within Bruker in 2012 and 2013.

From Bruker Nano Surfaces and Metrology 13 Oct 2011

Counterfeit drugs risk lives, threaten pharmaceutical industry in India

BBC News examines how counterfeit or substandard medicines are threatening India's fast-growing pharmaceutical industry, writing, "Worth over $12 billion, the industry is expected to grow more than four-fold in the coming decade," but fake drugs in the system are risking both the lives of patients and the reputation of drug makers.

12 Oct 2011

United Therapeutics to offer $210M of convertible senior notes due 2016

United Therapeutics Corporation today announced that it intends to offer, subject to market and other conditions, $210 million aggregate principal amount of convertible senior notes due 2016 to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended.

11 Oct 2011

Allos to complete merger with AMAG Pharmaceuticals

Allos Therapeutics, Inc. today announced that it continues to work with AMAG Pharmaceuticals, Inc. towards the completion of their merger, pending stockholder approval and satisfaction of the other conditions to closing described in Allos' definitive proxy statement filed with the SEC on September 15, 2011.

11 Oct 2011